TECHNICAL BULLETIN

☒NEW TEST ☒TEST CHANGE

NOTIFICATION DATE: 11/16/2023
EFFECTIVE DATE: 11/28/2023

PROMETHEUS Anser VDZ (ANSERVDZ)
PROMETHEUS Anser Ustekinumab (ANSERUST)

On the effective date, the PROMETHEUS Anser VDZ and PROMETHEUS Anser Ustekinumab tests will now be performed by Labcorp (LCA) using their proprietary DoseASSURE™ System. These tests will no longer be performed by Prometheus Laboratories.

The reference intervals for the tests will be updated.

Test Requirement/ Parameters	**New**	**Previous**	**New**	**Previous**
	Vedolizumab & Anti-Vedolizumab Ab	**Prometheus Anser VDZ**	**Ustekinumab & Anti-Ustekinumab Ab**	**Prometheus Anser Ustekinumab**
Submission Container/ Tube	Gold Top Tube		Gold Top Tube	
Specimen Volume/ Minimum Volume	2 mL serum (1 mL min)		2 mL serum (1 mL min)	
Reference Interval	Vedolizumab drug level		Ustekinumab drug level	
	<1.3 µg/mL	<1.6 µg/mL	<0.1 µg/mL	<1.6 µg/mL
	Anti-vedolizumab antibody		Anti-ustekinumab antibody	
	<25 ng/mL	<1.6 U/mL	<40 ng/mL	<1.6 U/mL
Computer Interface Code	**VEDOLIZ**	**ANSERVDZ**	**USTEKINUAB**	**ANSERUST**
Test Order	**PDM #1759547**	**PDM #1759072**	**PDM #235038**	**PDM #2059731**

If you have any questions, please contact Client Services at (800) 472-5757.

Northwell Health® Labs